Skip to Main Content

Paper Details

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
J Thorac Oncol
10
2023
ALK, EGFR, NSCLC, advanced NSCLC, early-stage NSCLC, mediastinal lymph node metastases, oncogenic drivers, osimertinib, patients
Author NameAffiliation
Amy L CummingsDavid Geffen School of Medicine at University of California los angeles
Amy L CummingsDavid Geffen School of Medicine at University of California los angeles
  • 1 - 2

Datasets

Release 1.2